34391-04-3
中文名称
左旋沙丁胺醇
英文名称
Salbutamol
CAS
34391-04-3
分子式
C13H21NO3
MDL 编号
MFCD00869868
分子量
239.31
MOL 文件
34391-04-3.mol
更新日期
2023/02/10 16:49:10
34391-04-3 结构式
基本信息
中文别名
左旋沙丁胺醇左旋沙丁胺醇盐酸盐
4-[2-(叔丁氨基)-1-羟乙基]-2-(羟甲基)苯酚
英文别名
(L)-ALBUTEROLLEVALBUTEROL
LEVALBUTEROL HCL
R-SALBUTAMOL HCL
(-)-alpha(sup1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedime
1,3-benzenedimethanol,alpha(sup1)-(((1,1-dimethylethyl)amino)methyl)-4-hydrox
alpha’-diol,alpha(sup1)-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alph
r-albuterol
Levalbutreol
2-(hydroxymethyl)-4-[1-hydroxy-2-(tert-butylamino)ethyl]phenol
LEVOSALBUTEROLHCL
1,3-Benzenedimethanol, a1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, (a1R)- (9CI)
1,3-Benzenedimethanol, a1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, (R)-
Levosalbutamol
m-Xylene-a,a'-diol, a1-[(tert-butylamino)methyl]-4-hydroxy-, (R)-(-)- (8CI)
2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-(tert-butylamino)ethyl]phenol
4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
Salbutamol
(R)-1-(4-Hydroxy-3-hydroxymethylphenyl)-2-(1,1-dimethylethylamino)ethanol
(R)-1-(4-Hydroxy-3-hydroxymethylphenyl)-2-tert-butylaminoethanol
所属类别
有机原料：氨基化合物常见问题列表
生物活性
Levalbuterol ((R)-Albuterol; (R)-Salbutamol) 是短效 β2-肾上腺素受体 (β2-adrenergic receptor) 激动剂和 Salbutamol 的活性 R 型对映异构体。Levalbuterol 是一种比 Salbutamol 更有效的支气管扩张试剂，可用于哮喘和慢性阻塞性肺疾病 (COPD) 的研究。体外研究
Levalbuterol (10 μM; 24 hours) induces 11β-HSD1 mRNA expression, however, it does not influence 11β-HSD2 expression in airway epithelial cells.Levalbuterol (10 μM; 24 hours) significantly reduces both LPS- and TNF-α-induced NF-κB activity while increasing GRE activation in an 11β-HSD1 dependent manner in a transformed mouse airway epithelial cell line.
RT-PCR
| Cell Line: | Murine Club (MTCC) cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours |
| Result: | Increased 11β-HSD1 mRNA expression selectively. |
体内研究
Levalbuterol (subcutaneous injection; 1 mg/kg; 14 days) significantly decreases pulmonary inflammation in OVA mice, demonstrated a decrease in eosinophilia and IgE.
| Animal Model: | C57BL/6 female mice with a pulmonary allergic model |
| Dosage: | 1 mg/kg |
| Administration: | Subcutaneous injection; 1 mg/kg; 14 days |
| Result: | Decreased pulmonary inflammation after OVA sensitization. |